

Research Questions

Why? Is there a genetic predisposition

Mechanism? Co-stimulatory signals? Preventable?

How long to avoid? Evidence of re-sensitization from tick and/or meat

Treatment (besides avoidance). IT? Anti-IgE?

Molecular Mimicry?

25

Research Questions

- ☐ Why? Is there a genetic predisposition
- ☐ Mechanism? Co-stimulatory signals? Preventable?
- ☐ How long to avoid? Evidence of re-sensitization from tick and/or meat
- ☐ Treatment (besides avoidance). IT? Anti-IgE?
- ☐ Molecular Mimicry?

Clinical Update

U.S. FOOD & DRUG ADMINISTRATION

A to Z Index | Follow FDA | En Español

Search FDA

Home | Food | Drugs | Medical Devices | Radiation-Emitting Products | Vaccines, Blood & Biologics | Animal & Veterinary | Cosmetics | Tobacco Products

News & Events

Home > News & Events > Newsroom > Press Announcements

FDA News Release

FDA approves new eczema drug Dupixent

SHARE | TWEET | LINKEDIN | PIN IT | EMAIL | PRINT

For Immediate Release March 28, 2017

Release

Español

The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

Inquiries

Media

Sarah Peddicord
301-796-2805

Andrea Fischer
301-796-0393

Consumers

888-INFO-FDA

Related Information

- FDA Approved Drugs: Questions and Answers